Glaxo has been required to issue a recall of pre-filled syringe/needle sets of Imigran Subject, a preparation of sumatriptan used for the acute treatment of severe migrane. 

Apparently, a small number of syringes may have needles protruding from the needle shield.

According to the recall notice issued by the Medicines and Healthcare Products Regulatory Agency (MHRA), “the risk to the patient of finding an affected syringe is extremely low; the implication of patient exposure to a syringe with a protruding needle is the potential risk of infection”.

So too for those involved in disposal through once used the combined needle device should be placed into a suitable sharps bin or back into its container since this is quite robust, and if closed securely can then be disposed into a more general clinical waste container.

The used drug vial and syringe may contain a detectable, though ultimately trivial residue of drug substance and in the mind of officialdom it may be necessary to manage this waste as for other pharmaceutical or pharmaceutical-contaminated sharps and ensure this is disposed only by incineration. However, for wastes that might comprise at most a single pack of two injectors, and two empty drug vials inside a secure pack, pragmatism might suggest that since the wastes will arise in the community – the product is intended for patient self-administration – a less formal approach to segregation and disposal would be more than adequate.

http://www.mhra.gov.uk/home/groups/is-md/documents/drugalert/con329308.pdf